Evoke Pharma Inc. (EVOK)

[dmsrz8]

Read the last sentence off the 8-k...and then stop talking...

“The FDA approval of GIMOTI allows Evoke to access its existing $5 million line of credit from EVERSANA, to support manufacturing and other aspects of GIMOTI’s commercialization. As of May 31, 2020, the Company’s cash and cash equivalents were approximately $4.7 million. Evoke believes, based on its current operating plan, that its cash and cash equivalents, together with the EVERSANA line of credit, will support the company’s operations into 2021, without consideration of potential GIMOTI revenue”